Get the Stockscreener App
588.34
1.43%
-8.51
After Hours:
586.33
-2.01
-0.34%
Regeneron Pharmaceuticals Inc stock is traded at $588.34, with a volume of 653.98K.
It is down -1.43% in the last 24 hours and up +0.08% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$596.85
Open:
$586.85
24h Volume:
653.98K
Relative Volume:
0.61
Market Cap:
$62.45B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
14.98
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
-1.01%
1M Performance:
+0.08%
6M Performance:
-20.28%
1Y Performance:
-40.00%
1-Day Range:
$582.37
$591.64
1-Week Range:
$582.37
$617.52
52-Week Range:
$520.50
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ONC
Beigene Ltd Adr
|
241.43 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Initial Data on Multiple Myeloma Drug Encouraging - Zacks Investment Research
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Promising Results In LINKER-MM2 Trial For Linvoseltamab - simplywall.st
Tidal Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
USS Investment Management Ltd Sells 1,440 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea - Seeking Alpha
Vident Advisory LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Williams Jones Wealth Management LLC. Sells 715 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lowered by Jacobs Levy Equity Management Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Royal Bank of Canada - MarketBeat
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Quantinno Capital Management LP - MarketBeat
Janus Henderson Group PLC Sells 84,661 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Strive Asset Management LLC Invests $419,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to acquire bankrupt genetic testing firm 23andMe for US$256 million - Proactive Investors
Litigators of the Week: A $406.8M Win for Regeneron in Antitrust Trial Showdown With Cholesterol Drug Rival Amgen - Law.com
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
Regeneron Pharmaceuticals Reveals Trial Data of Drug Combination to Treat Multiple Myeloma - marketscreener.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lifted by Scientech Research LLC - MarketBeat
Regeneron (REGN) Reports Promising Trial Results for Linvoseltamab in Multiple Myeloma | REGN Stock News - GuruFocus
Breakthrough: Regeneron's Multiple Myeloma Drug Shows 90% Response Rate in New Combination Therapy Trial - Stock Titan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer - Insider Monkey
Bayer wins China approval for high-dose Eylea (REGN:NASDAQ) - Seeking Alpha
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - Benzinga
Worldquant Millennium Advisors LLC Has $75.02 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Enters into Agreement to Acquire Consumer Genetics Business - thehudsonindependent.com
Voloridge Investment Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Woodline Partners LP Buys 3,862 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Twinbeech Capital LP Has $17.91 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $890.60 Average Price Target from Analysts - MarketBeat
Tema Etfs LLC Invests $4.17 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pathstone Holdings LLC Sells 1,254 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to buy 23andMe for $256M in court-supervised sale - MSN
1,064 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Sig Brokerage LP - MarketBeat
ProShare Advisors LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Man Group plc Sells 24,377 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sherbrooke Park Advisers LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Raiffeisen Bank International AG Invests $3.51 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Teza Capital Management LLC Acquires 429 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Soleus Capital Management L.P. Takes $1.64 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Victrix Investment Advisors Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Vestal Point Capital LP Invests $14.25 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - AOL.com
Triglav Skladi D.O.O. Invests $1.79 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's 23andMe StealSmart Genetics Play That Won't Cure Near-Term Growth Pains - Seeking Alpha
Mufg Securities Americas Inc. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals to Acquire 23andMe for $256M - MSN
23andMe sold to Regeneron for $256M in court-supervised bankruptcy, sans Lemonaid. And is it worth it? - Telehealth and Telecare Aware
Nuveen Asset Management LLC Sells 211,009 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Toronto Dominion Bank Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What Does Regeneron's Purchase of 23andMe Mean for Privacy? - Bank information security news
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):